Kyle Guse

Director

CFO Board Member

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2023	Atossa Therapeutics, Inc. (ATOS)	General Counsel and Secretary	$248,358	—	—	$342,790	—	$580,483	$1,171,631
2022	Atossa Therapeutics, Inc. (ATOS)	General Counsel and Secretary	$466,658	—	—	$788,918	$239,395	$32,900	$1,527,871
2021	Atossa Therapeutics, Inc. (ATOS)	General Counsel and Secretary	$456,700	—	—	$2,108,013	$205,515	$31,400	$2,801,628
2020	Atossa Therapeutics, Inc. (ATOS)	General Counsel and Secretary	$421,056	—	—	$761,335	$189,475	$13,600	$1,385,466
2019	Atossa Therapeutics, Inc. (ATOS)	Chief Financial Officer, General Counsel and Secretary	$421,056	—	—	$1,700,291	$189,475	$18,650	$2,329,472
2018	Atossa Therapeutics, Inc. (ATOS)	Chief Financial Officer, General Counsel and Secretary	$408,000	—	—	$329,006	$333,600	$18,325	$1,088,931

Executive changes

Appointed director of the Board at Cerenome, Inc. (CNSY)
2025-04-18

Earnings-call appearances

No earnings-call appearances recorded yet.